Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan

Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news